Caribou Biosciences, Inc. — fact timeline

Caribou Biosciences, Inc. shareholders approved Approval of the Adjournment of the 2026 Annual Meeting to a Later Date or Dates, if Necessary, to Permit Further Solicitation and Voting of Proxies in the Event There are not Sufficient Votes in Favor of Proposal 3 or if There are not Sufficient Shares Present to Establish a Quorum. at the 2026-06-17 meeting.

“Proposal 4 - Approval of the Adjournment of the 2026 Annual Meeting to a Later Date or Dates, if Necessary, to Permit Further Solicitation and Voting of Proxies in the Event There are not Sufficient Votes in Favor of Proposal 3 or if There are not Sufficient Shares Present to Establish a Quorum. The stockholders approved the adjournment of the 2026 annual meeting, if necessary, by the following votes: Votes For Votes Against Votes Abstain Broker Non-Votes 37,615,389 3,418,004 106,383 27,098,425”

Caribou Biosciences, Inc. shareholders rejected Approval of an Amendment to the Company's Amended and Restated Certificate of Incorporation to Provide for Exculpation of Officers from Certain Breaches of Fiduciary Duty to the Fullest Extent Permitted by the General Corporation Law of the State of Delaware at the 2026-06-17 meeting.

“Proposal 3 - Approval of an Amendment to the Company's Amended and Restated Certificate of Incorporation to Provide for Exculpation of Officers from Certain Breaches of Fiduciary Duty to the Fullest Extent Permitted by the General Corporation Law of the State of Delaware The stockholders did not approve the above-referenced amendment to the Company's amended and restated certificate of incorporation. The voting results on this proposal were as follows: Votes For Votes Against Votes Abstain Broker Non-Votes 37,483,637 3,513,785 142,354 27,098,425”

Caribou Biosciences, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2026-06-17 meeting.

“Proposal 2 - Ratification of Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, by the following votes: Votes For Votes Against Votes Abstain Broker Non-Votes 67,457,482 337,911 442,808 0”

Caribou Biosciences, Inc. shareholders approved Election of Three Class II Directors at the 2026-06-17 meeting.

“Proposal 1 - Election of Three Class II Directors Each of the following nominees was elected to serve as a Class II director, to hold office until the Company’s 2029 annual meeting of stockholders and until their respective successor is duly elected and qualified or until their earlier death, resignation, or removal. The voting results on this proposal were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Andrew Guggenhime, M.B.A. 31,554,511 9,585,265 27,098,425 David Johnson, M.B.A. 31,725,652 9,414,124 27,098,425 Nancy Whiting, Pharm.D. 31,694,175 9,445,601 27,098,425”

Caribou Biosciences, Inc. reported financial results for the first quarter of 2026.

“reported financial results for the first quarter of 2026 and provided a business update.”

Caribou Biosciences, Inc. reported the year ended December 31, 2025 results: revenue $11.2 million, net income net loss of $148.1 million, EPS $1.59 per share.

“Fourth quarter and full year 2025 financial results Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.9 million for the three months ended December 31, 2025 and $11.2 million for full year 2025, compared to $2.1 million and $10.0 million, respectively, for the same periods in 2024. The increase for full year 2025 was primarily driven by a net increase in revenues related to prior licenses of certain of Caribou's intellectual property to third parties. R&D expenses: Research and development expenses were $23.8 million for the three months ended December 31, 2025 and $109.4 million for full year 2025, compared to $30.5 million, and $130.2 million respectively, for the same periods in 2024. The decrease for full year 2025 was primarily due to lower R&D and personnel-related expenses related to the reduction in workforce and strategic pipeline prioritization, external contract manufacturing and contract research organization activitie”

Caribou Biosciences, Inc. reported the three months ended December 31, 2025 results: revenue $3.9 million, net income net loss of $26.5 million, EPS $0.28 per share.

“Fourth quarter and full year 2025 financial results Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.9 million for the three months ended December 31, 2025 and $11.2 million for full year 2025, compared to $2.1 million and $10.0 million, respectively, for the same periods in 2024. The increase for full year 2025 was primarily driven by a net increase in revenues related to prior licenses of certain of Caribou's intellectual property to third parties. R&D expenses: Research and development expenses were $23.8 million for the three months ended December 31, 2025 and $109.4 million for full year 2025, compared to $30.5 million, and $130.2 million respectively, for the same periods in 2024. The decrease for full year 2025 was primarily due to lower R&D and personnel-related expenses related to the reduction in workforce and strategic pipeline prioritization, external contract manufacturing and contract research organization activitie”

Caribou Biosciences, Inc. announced a restructuring with charges of approximately $2.5 million to $3.5 million in total affecting GALLOP phase 1 clinical trial for CB-010 in lupus, AMpLify phase 1 clinical trial for CB-012, and preclinical research (47 employees, or approximately 32% of the Company).

“half of 2027. In connection with the strategic pipeline prioritization and the workforce reduction, the Company currently estimates it will incur expenses of approximately $2.5 million to $3.5 million in total, consisting primarily of cash severance costs, benefits, and transition support services for impacted employees, and future costs to wind down its GALLOP”

Sriram Ryali was appointed as Chief Financial Officer at Caribou Biosciences, Inc..

“On January 2, 2025, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), announced the appointment of Sriram Ryali, age 44, to the position of Chief Financial Officer (“CFO”) of the Company, effective as of January 2, 2025 (the “Start Date”).”

Ryan Fischesser was appointed as Interim Principal Financial Officer and Interim Principal Accounting Officer at Caribou Biosciences, Inc..

“On September 23, 2024, Caribou Biosciences, Inc. (the “Company”) designated Ryan Fischesser, the Company’s current Vice President of Finance and Controller, as the Company’s interim principal financial officer and interim principal accounting officer, effective as of 5:00 p.m. Pacific time on September 27, 2024.”

Jason O'Byrne resigned as Chief Financial Officer at Caribou Biosciences, Inc..

“Mr. O’Byrne serves as the Company’s principal financial officer and principal accounting officer through September 27, 2024, his final day with the Company.”

Ryan Fischesser was appointed as principal accounting officer at Caribou Biosciences, Inc..

“The Company intends to appoint Ryan Fischesser, the Company’s current Vice President of Finance and Controller, to assume the role of the Company’s principal accounting officer, effective as of the close of business on September 27, 2024.”

Jason O'Byrne resigned as Chief Financial Officer at Caribou Biosciences, Inc..

“On September 1, 2024, Jason O’Byrne, the Chief Financial Officer of Caribou Biosciences, Inc. (the “Company”), informed the Company of his intent to resign from his position, effective September 27, 2024, to pursue another opportunity.”

Caribou Biosciences, Inc. announced a restructuring with charges of approximately $0.5 million to $1.0 million affecting allogeneic CAR-NK platform (21 positions, or approximately 12%).

“in cash, cash equivalents, and marketable securities as of June 30, 2024. In connection with the workforce reduction, the Company currently estimates it will incur approximately $0.5 million to $1.0 million in costs, consisting primarily of cash severance costs, benefits, and transition support services for impacted employees, which the Company expects to recognize”

Caribou Biosciences, Inc. reported the quarter ended March 31, 2024 results: revenue $2.4 million.

“Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $2.4 million for the three months ended March 31, 2024, compared to $3.5 million for the same period in 2023.”

Caribou Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

“On March 11, 2024, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2023 and providing a business update.”

Syed Rizvi departed as Chief Medical Officer at Caribou Biosciences, Inc..

“As previously announced on December 12, 2023, Syed Rizvi, M.D., the Chief Medical Officer of Caribou Biosciences, Inc. (the “Company”), will be leaving the Company effective December 31, 2023.”

Syed Rizvi departed as Chief Medical Officer at Caribou Biosciences, Inc..

“Syed Rizvi, M.D., the Chief Medical Officer of Caribou Biosciences, Inc. (the “Company”), will be leaving the Company effective December 31, 2023.”

Caribou Biosciences, Inc. reported third quarter of 2023 results: revenue $23.7 million.

“will be sufficient to fund its current operating plan into Q4 2025. Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $23.7 million for the three months ended September 30, 2023, compared to $3.3 2 million for the same period 2022. The increase was primarily due to $21.5 million in revenue recognized under”

Caribou Biosciences, Inc. terminated Collaboration and License Agreement with AbbVie Manufacturing Management Unlimited Company valued at Agreement terminated for convenience by AbbVie (effective 2023-10-25).

“On September 26, 2023, Caribou Biosciences, Inc. (the “Company”) received notice from AbbVie Manufacturing Management Unlimited Company (“AbbVie”) that AbbVie has elected to terminate the Collaboration and License Agreement, as amended, by and between the Company and AbbVie, dated February 9, 2021 (the “Agreement”).”

Caribou Biosciences, Inc. reported second quarter of 2023 results: revenue $3.8 million.

“will be sufficient to fund its current operating plan into Q4 2025. Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.8 million for the three months ended June 30, 2023, compared to $4.2 million for the same period 2022. The decrease was primarily due to a reduction in revenue recognized under the AbbVie”

Caribou Biosciences, Inc. entered into Underwriting Agreement with BofA Securities, Inc., SVB Securities LLC, and Evercore Group L.L.C., as representatives of the several underwriters (effective 2023-07-13).

“On July 13, 2023, Caribou Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., SVB Securities LLC, and Evercore Group L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 19,230,769 shares of its common stock”

Caribou Biosciences, Inc. reported preliminary financial results for the three and six months ended June 30, 2023.

“Preliminary unaudited cash, cash equivalents, and marketable securities as of June 30, 2023 Caribou Biosciences, Inc. (the “Company”) is providing certain preliminary financial results. On a preliminary unaudited basis, the Company expects its cash, cash equivalents, and marketable securities as of June 30, 2023 to be approximately $292.5 million.”

Caribou Biosciences, Inc. entered into Voting Agreement with Pfizer Inc. (effective 2023-06-29).

“On June 29, 2023, the Company and Pfizer also entered into a Voting Agreement (the “Voting Agreement”), pursuant to which, for a period of 12 months, Pfizer agreed to cause any voting securities of the Company that Pfizer beneficially owns (within the meaning of Rules 13d-3 or 13d-5 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) in excess of 4.99% of the then issued and outstanding voting securities of the Company to be voted (i) with respect to any matter directly relating to remuneration of directors, directors’ insurance, or indemnification or release from liability of directors, in a manner proportionally consistent with the votes properly cast for and against by holders of voting securities not beneficially owned by Pfizer, and (ii) with respect to any other matter in which Pfizer shall have the right to vote such voting securities, in accordance with the recommendation of the Board of Directors of the Company or any applicable committee thereof.”

Caribou Biosciences, Inc. entered into Securities Purchase Agreement with Pfizer Inc. valued at approximately $25 million (effective 2023-06-29).

“On June 29, 2023, Caribou Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with Pfizer Inc. (“Pfizer”), pursuant to which the Company, in a private placement transaction (the “Private Placement”), agreed to issue and sell to Pfizer 4,690,431 shares (the “Shares”) of common stock, par value $0.0001 per share, at a purchase price of $5.33 per share, for aggregate gross proceeds to the Company of approximately $25 million.”

Caribou Biosciences, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-06-15 meeting.

“Proposal 2 - Ratification of Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, by the following votes: Votes For Votes Against Votes Abstain 45,652,597 51,771 82,435”

Caribou Biosciences, Inc. shareholders approved Election of Two Class I Directors at the 2023-06-15 meeting.

“Proposal 1 - Election of Two Class I Directors Each of the following nominees was elected to serve as a Class II director, to hold office until the Company’s 2026 annual meeting of stockholders and until their respective successor is duly elected and qualified or until their earlier death, resignation, or removal. Nominee Votes For Votes Withheld Broker Non-Votes Andrew Guggenhime, M.B.A. 31,032,443 5,325,715 9,428,645 David L. Johnson, M.B.A. 31,840,467 4,517,691 9,428,645 Nancy Whiting, Pharm.D. 31,863,074 4,495,084 9,428,645”

Caribou Biosciences, Inc. reported three months ended March 31, 2023 results: revenue $3.5 million, net income $28.0 million net loss.

“First Quarter 2023 Financial Results Cash, cash equivalents, and marketable securities: Caribou had $291.0 million in cash, cash equivalents, and marketable securities as of March 31, 2023, compared to $317.0 million as of December 31, 2022. Caribou expects its cash, cash equivalents, and marketable securities will be sufficient to fund its current operating plan into 2025. Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.5 million for the three months ended March 31, 2023, compared to $2.7 million for the same period 2022. The increase was primarily due to revenue recognized under the Collaboration and License Agreement with AbbVie and other license agreements. R&D expenses: Research and development expenses were $25.7 million for the three months ended March 31, 2023, compared to $13.9 million for the same period in 2022. The increase was primarily due to costs to advance pipeline programs, including the ANTLER and CaMMouflage”

Caribou Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.

“On March 9, 2023, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2022 and providing a business update.”

Ryan Fischesser changed role as principal accounting officer at Caribou Biosciences, Inc..

“The Company’s Vice President of Finance and Controller, Ryan Fischesser, who was previously serving as the Company’s principal accounting officer, will continue serving as the Company’s Vice President of Finance and Controller but not as the Company’s principal accounting officer, effective as of December 15, 2022.”

Jason V. O'Byrne was appointed as principal accounting officer at Caribou Biosciences, Inc..

“On December 15, 2022, Caribou Biosciences, Inc. (the “Company”) appointed Jason V. O’Byrne, its Chief Financial Officer, as the Company’s principal accounting officer.”

Caribou Biosciences, Inc. reported the third quarter of 2022 results: revenue $3.3 million, net income $26.6 million.

“of September 30, 2022, compared to $413.5 million as of December 31, 2021. Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.3 million for the three months ended September 30, 2022, compared to $4.0 million for the same period in 2021. The decrease was primarily due to a decrease in revenue under the AbbVie”

David L. Johnson was appointed as Class II director at Caribou Biosciences, Inc..

“increased the size of the Board from seven to eight directors and unanimously agreed to extend an offer to David L. Johnson, M.B.A., to serve as a Class II director of the Company.”

Dara Richardson-Heron was appointed as Class III Director at Caribou Biosciences, Inc..

“On November 4, 2021, the Board of Directors (the “Board”) of Caribou Biosciences, Inc., a Delaware corporation (the “Company”), increased the size of the Board from six to seven directors and unanimously agreed to extend an offer to Dara Richardson-Heron, M.D., to serve as a Class III director of the Company.”

Ran Zheng was appointed as Class I Director at Caribou Biosciences, Inc..

“On September 24, 2021, the Board of Directors (the “Board”) of Caribou Biosciences, Inc., a Delaware corporation (the “Company”), increased the size of the Board from five to six directors and unanimously agreed to extend an offer to Ran Zheng to serve as a Class I director of the Company, which offer Ms. Zheng accepted on September 24, 2021.”

Nancy C. Whiting was appointed as Director at Caribou Biosciences, Inc..

“unanimously agreed to extend an offer to Nancy C. Whiting, Pharm. D. to serve as a Class II director of the Company, which offer Dr. Whiting accepted on August 24, 2021.”

Jeffrey Long-McGie resigned as Director at Caribou Biosciences, Inc..

“Effective as of July 27, 2021, Mr. Jeffrey Long-McGie resigned from the Company’s board of directors in connection with the closing of the Offering.”